The acquisition gives Danaher ownership of a producer of research tools, such as antibodies and reagents, that are used in drug discovery experiments.

With its ability to process vast amounts of data and identify patterns, AI can significantly reduce the time and cost involved in developing new drugs.

Is pharma up to the challenge of delivering the personalized and contextual experiences doctors have come to expect? Too often, the answer is no.

Neumora’s filing late Friday, along with that of radiopharmaceutical startup RayzeBio earlier this week, could be an important test of the biotech IPO market.

Biotech's IPO drought has endured into late August, but a small group of drugmakers are now in line ahead of a fall that analysts predict could be busier.

The company plans to enroll roughly 17,000 people in three Phase 3 trials of the drug, including a large cardiovascular study set to begin later this year.

After trial results showed the obesity drug can prevent heart attacks, the company now has data indicating it can help people with heart failure, too.

The drugmaker's lawsuit comes the week before the Biden administration is set to announce the first 10 drugs subject to negotiated prices in 2026.

According to one analyst, the approval was the last hurdle keeping Sandoz’s Tyruko from directly competing in the U.S. market against Biogen’s inflammation-regulating medicine Tysabri.

The subsidiary, called Cordavis, will work directly with manufacturers to market or co-produce low-cost biologic drugs, starting with Novartis’ Humira copy.

Bristol Myers Squibb is among those backing the company, which claims the manufacturing capacity at its New Jersey plant can surpass that of conventional CDMO facilities. 

The deal, worth up to $500 million, is a bet by the drug rights dealmaker on the uncertain commercial prospects of Ferring's gene therapy Adstiladrin.